Could ditching a common drug sharpen the mind in schizophrenia?

NCT ID NCT06562608

First seen Jun 26, 2026 · Last updated Jul 10, 2026 · Updated 2 times

Summary

This study looks at whether stopping unnecessary anticholinergic drugs (benztropine or trihexyphenidyl) can improve thinking, quality of life, and brain function in people aged 40-70 with schizophrenia or schizoaffective disorder. Participants will either stay on their medication or undergo deprescribing as part of routine care, with follow-ups over 6 months. The goal is to see if reducing these drugs leads to better cognitive performance and daily functioning.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
benztropine or trihexyphenidyl (anticholinergic drugs)
What this could lead to
If successful, this could show that reducing unnecessary anticholinergic medications improves cognitive function and daily living in older adults with schizophrenia.
What could go wrong
This is a small Phase 4 study with 105 participants, so results may not apply broadly. Deprescribing may not lead to significant improvements, and some participants might experience withdrawal or return of side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SCHIZOAFFECTIVE DISORDER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • UPMC Western Psychiatric Hospital/University of Pittsburgh

    RECRUITING

    Pittsburgh, Pennsylvania, 15213, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.